

# Amir Garakani, M.D.

## PUBLICATION LIST

### PEER-REVIEWED PUBLICATIONS

1. Marshall RD, **Garakani A**. Psychobiology of the acute stress response and its relationship to the psychobiology of PTSD. *Psychiatr Clin North Am*. 2002; 25:385–395.
2. Quitkin FM, **Garakani A**, Kelly KE. Electrolyte-balanced sports drink for polydipsia-hyponatremia in schizophrenia. *Am J Psychiatry*. 2003; 160:385–386.
3. **Garakani A**, Win T, Virk S, Gupta S, Kaplan DS, Masand PS. Comorbidity of irritable bowel syndrome in psychiatric patients: A review. *Am J Ther*. 2003; 10:61–67.
4. **Garakani A**, Hirschowitz J, Katz CL. General disaster psychiatry. *Psychiatr Clin North Am*. 2004; 27:391-406.
5. **Garakani A**, Mathew SJ, Charney DS. Neurobiology of anxiety disorders and implications for treatments. *Mt Sinai J Med*. 2006; 73(7):941–949.
6. **Garakani A**, Buchsbaum MS, Newmark RE, Goodman C, Aaronson CJ, Martinez JM, Torosjan Y, Chu K, Gorman JM. The effect of doxapram on brain imaging in patients with panic disorder. *Eur Neuropsychopharmacol*. 2007; 17(10):672–686.
7. **Garakani A**, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. *Int Clin Psychopharmacol*. 2008; 23(5):269–275.
8. Mathew SJ, **Garakani A**, Reinhard JF, Oshana S, Donahue S. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study. *Clin Ther*. 2008; 30(9):1658–1666.
9. **Garakani A**, Martinez JM, Aaronson CJ, Voustianiouk A, Kaufmann H, Gorman JM. Effect of medication and psychotherapy on heart rate variability in panic disorder. *Depress Anxiety*. 2009; 26(3):251-258.
10. Billick SB, Perez DL, **Garakani A**. A clinical study of competency to consent to hospitalization and treatment in geriatric inpatients. *J Forensic Sci*. 2009;54(4):943–946.
11. Krystal JH, Mathew SJ, D’Souza DC, **Garakani A**, Gunduz-Bruce H, Charney DS. Potential psychiatric applications of metabotropic glutamate receptor glutamate receptor agonists and antagonists. *CNS Drugs*. 2010; 24(8):669–693.
12. Hirschowitz J, Kolevzon A, **Garakani A**. The pharmacological treatment of bipolar disorder: the question of modern advances. *Harv Rev Psychiatry*. 2010;18:266–278.
13. **Garakani A**. Urinary retention with a high dose of escitalopram. *Gen Hosp Psychiatry*. 2010; 32(6):e11-12.
14. Martinez JM, **Garakani A**, Kaufmann H, Aaronson CJ, Gorman JM. Heart rate and blood pressure changes during autonomic nervous system challenge in panic disorder patients (impact of severity of illness). *Psychosom Med*. 2010;72(5):442–449.
15. Martinez JM, **Garakani A**, Yehuda R, Gorman JM. Pro-inflammatory and “resiliency” proteins in the CSF of patients with major depression. *Depress Anxiety*. 2012;29(1):32–38.

16. Goldberg JF, **Garakani A**, Ackerman SH. Clinician- versus self-rated screening for bipolar disorder among inpatients with mood symptoms and substance abuse. *J Clin Psychiatry*. 2012;73(12):1525–1530. \*Designated as a CME Activity\*
17. **Garakani A**, Welch AK, Newcorn JH. A 66-Year-Old Woman with Facial Tics and Social Impairment. *Psychiatric Annals*. 2013;43(1):10–14. \*Designated as a CME Activity\*
18. **Garakani A**, Martinez, JM, Yehuda R, Gorman JM. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. *J Affect Disord*. 2013;146(2):262–5.
19. Saraiya A, **Garakani A**, Billick SB. Mental health approaches to child victims of acts of terrorism. *Psychiatr Q*. 2013; 84(1):115-24.
20. **Garakani A**, Mendelsohn N. Iphis and Anaxarete in Ovid’s Metamorphoses: Poem of the Shut-Out Lover. *Am J Psychiatry*. 2013; 170(7):721-2.
21. Liu MC, **Garakani A**, Krauskopf KA, Robinson-Papp J. A case of reversible neuropsychiatric symptoms in HIV due to toxic leukoencephalopathy . *Innov Clin Neurosci*. 2013; 10(9-10):26-29.
22. Leibu E, **Garakani A**, McGonigle DP, Liebman LS, Loh D, Bryson EO, Kellner CH. ECT for Catatonia in a Patient with Schizophrenia and Synthetic Cannabinoid Abuse: A Case Report. *J ECT*. 2013; 29(4):e61-62.
23. Majeske MF, **Garakani A**, Maloutas E, Bryson EO, Kellner CH. Transient Febrile Reaction After Electroconvulsive Therapy (ECT) in a Young Adult with Intellectual Disability and Bipolar Disorder. *J ECT*. 2013; 29(4):e63-5.
24. Billick SB, **Garakani A**. Ophthalmologic screening in 25 consecutive geriatric psychiatric inpatient admissions. *Psychiatr Q*. 2014;85(1):49-56.
25. **Garakani A**. A Case of Reversible Erectile Dysfunction with Topiramate for Alcohol Dependence. *Prim Care Companion CNS Disord*. 2014;16(1):doi:10.4088/PCC.13i01565.
26. **Garakani A**, Murrrough JW, Iosifescu DV. Advances in psychopharmacology for anxiety disorders. *FOCUS (Am Psychiatr Publ)*. 2014; 12(2):152-162.
27. **Garakani A**, Welch AK, Jaffe RJ, Protin CA, McDowell DM. Psychosis and low cyanocobalamin in a patient abusing nitrous oxide and cannabis. *Psychosomatics*. 2014; 55(6):715-9
28. **Garakani A**, Shalenberg E, Burstin SC, Brendel RW, Appel JM. Voluntary psychiatric hospitalization and patient-driven requests for discharge: a statutory review. *Harv Rev Psychiatry*. 2014;22(4):241-249.
29. **Garakani A**, Mitton AG. New-Onset Panic, Depression with Suicidal Thoughts and Somatic Symptoms in a Patient with a History of Lyme Disease. *Case Rep Psychiatry*. 2015; 2015:457947. doi:10.1155/2015/457947
30. Martinez JM, **Garakani A**, Aaronson C, Gorman JM. Heart rate and respiratory response to doxapram in patients with panic disorder. *Psychiatry Res*. 2015;227(1):32–8.
31. **Garakani A**, Jaffe RJ, Savla D, Welch AK, Protin CA, Bryson EO, McDowell DM. Neurologic, psychiatric and other medical manifestations of nitrous oxide abuse: a systematic review of the case literature. *Am J Addict*. 2016; 25(5):358-369.
32. Radhakrishnan R, **Garakani A**, Gross LS, Goin MK, Pine J, Slaby AE, Sumner CR, Baron DA. Neuropsychiatric aspects of concussion. *Lancet Psychiatry*. 2016; 3(12):1166-1175.

33. **Garakani A**, Abdullah HM, Chang CM, Mendelsohn N, Lapidus KAB. Opinions regarding benzodiazepine teaching and prescribing among trainees in psychiatry. *Acad Psychiatry*. 2017 Jul 6. doi: 10.1007/s40596-017-0750-0. [Epub ahead of print]

#### **INVITED CONTRIBUTIONS**

1. **Garakani A**, Billick SB. Review of: Kidnapping: An Investigator's Guide to Profiling. *J Forensic Sci*. 2008; 53(6):1490.

#### **BOOKS**

1. Foreman T, Dickstein L, **Garakani A**, editors. *A Resident's Guide to Surviving Psychiatric Training*, 2nd Edition. Arlington: American Psychiatric Association; 2007.

#### **ELECTRONIC BOOKS**

2. Foreman T, Dickstein L, **Garakani A**, Jordan A, Richards M, editors. *A Resident's Guide to Surviving Psychiatric Training, 3rd Edition*. Arlington: American Psychiatric Association; 2015.

#### **BOOK CHAPTERS**

1. **Garakani A**, Schlechter A. Patient 18: A 16-year-old girl with amnesia. In: Kolevzon A, Stewart D, editors. *Psychiatry Pearls*. Philadelphia: Hanley and Belfus; 2004, p. 61–64.
2. West RL, **Garakani A**. Patient 50: A 33-year-old man with rage and threatening behavior. In: Kolevzon A, Stewart D, editors. *Psychiatry Pearls*. Philadelphia: Hanley and Belfus; 2004, p. 184–186.
3. **Garakani A**, Anand A, Charney DS. Abnormalities in catecholamines and the pathophysiology of bipolar disorder. In: Soares JC, Young AH, editors. *Bipolar Disorders: Basic Mechanisms and Therapeutic Implications*. 2nd Edition. New York: Informa Healthcare; 2007. p. 33–65.
4. **Garakani A**, Murrough J, Charney DS, Bremner, JD. The neurobiology of anxiety disorders. In: Charney DS, Nestler EJ, editors. *Neurobiology of Mental Illness*. 3rd edition. New York: Oxford University Press, USA; 2008. p. 605–628.
5. Amiel JM, Mathew SJ, **Garakani A**, Neumeister A, Charney DS. Neurobiology of Anxiety Disorders. In: Schatzberg AF, Nemeroff CB, editors. *American Psychiatric Publishing Textbook of Psychopharmacology*. 4th edition. Washington, D.C.: American Psychiatric Publishing, Inc.; 2009. p. 965–985.
6. **Garakani A**, Neumeister A, Bonne O, Charney DS. Anxiety disorders: neurochemical aspects. In: Sadock BJ, Sadock VA, Ruiz P, editors. *Kaplan and Sadock's Comprehensive Textbook of Psychiatry*. 9th edition. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 1871–1881.
7. **Garakani A**, Siever LJ. Schizotypal Personality Disorder. In: Cautin RL, Lilienfeld SO, editors. *The Encyclopedia of Clinical Psychology*. Malden, Oxford: John Wiley & Sons, Inc. 2015; p. 1–7.
8. Ehrlich YA, **Garakani A**, Pavlos SR, Siever L. Psychiatry: Personality disorders. In: Nabel EG, editor. *Scientific American Medicine* [online]. Hamilton (ON): Decker Intellectual Properties; September 2014. DOI: 10.2310/7900.1319. Available at: <http://www.sciammedicine.com>.

9. Shenoy A, Fischer R, **Garakani A**. Sleep-Wake Disorders. In: Goodman WK, Simon AB, New A, editors. Mount Sinai Expert Guides: Psychiatry. Chichester, West Sussex: John Wiley & Sons, Ltd. 2017, p. 207-216.
10. Appel JM, **Garakani A**, Kunz M. Forensic Psychiatry. In: Goodman WK, Simon AB, New A, editors. Mount Sinai Expert Guides: Psychiatry. Chichester, West Sussex: John Wiley & Sons, Ltd. 2017, p. 368-372.

#### **SELECTED ABSTRACTS**

1. Gupta S, Masand PS, Schwartz TL, Kaplan DS, Virk S, Hameed A, Lockwood K, **Garakani A**, Wade M. Does a preexisting anxiety disorder predict response to paroxetine in IBS? Proceedings of the 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, U.S.A., May 2001.
2. **Garakani A**, Aaronson CJ, Martinez JM, Buchsbaum MS, Gorman JM. The effect of cognitive behavioral therapy on brain imaging and neuroendocrine responses in patients with panic disorder. Proceedings of the 43rd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 2004. Published in: *Neuropsychopharmacology* 2004; 29, Abstract 55:S145.
3. Martinez JM, Aaronson CJ, **Garakani A**, Gorman JM. Effect of Medication and Psychotherapy on Heart Rate Variability in Panic Disorder. Proceedings of the 26th Anxiety Disorders Association of America (ADAA) Annual Conference, Miami, FL, U.S.A., March 2006. Selected for publication in: *Depression and Anxiety* 2007; 24:296–7.
4. **Garakani A**, Buchsbaum MS, Newmark RE, Martinez JM, Aaronson CJ, Goodman C, Chu K, Gorman JM. The Effect of Doxapram on Brain Imaging in Patients with Panic Disorder. Proceedings of the 62nd Annual Society of Biological Psychiatry Scientific Convention and Meeting, May 18, 2007. Published in: *Biological Psychiatry* 2007; Abstract NR157:51S.
5. **Garakani A**, Aloysi AS, Marcus S, Martinez JM, Katz CL. Patient Request for Discharge from Voluntary Psychiatric Hospitalization: A Chart Review. Proceedings of the 61<sup>st</sup> Annual Institute of Psychiatric Services Meeting of the American Psychiatric Association, New York, NY, U.S.A., October 8, 2009.
6. **Garakani A**. Voluntary Admission and Patient-Driven Discharge Procedures. Proceedings of the 42nd Annual Meeting of the American Academy of Psychiatry and the Law. Boston, MA, U.S.A., October 27, 2011.
7. **Garakani A**, Goldberg JF. Parsing the Effects of Comorbid Adult ADHD and Substance Misuse on Affective Lability in Bipolar Disorder. Proceedings of the 167th Annual Meeting of the American Psychiatric Association, New York, NY, U.S.A., May 2014.
8. **Garakani A**. Voluntary Admission and Patient-Driven Discharge Procedures. Proceedings of the 42nd Annual Meeting of the American Academy of Psychiatry and the Law. Boston, MA, U.S.A., October 27, 2011.
9. **Garakani A**, Goldberg JF. Parsing the Effects of Comorbid Adult ADHD and Substance Misuse on Affective Lability in Bipolar Disorder. Proceedings of the 167<sup>th</sup> Annual Meeting of the American Psychiatric Association, New York, NY, U.S.A., May 2014.
10. **Garakani A**, Chang CM, Mendelsohn N, Lapidus, KAB. Opinions Regarding Benzodiazepine Use among Trainees in Psychiatry. Proceedings of the 67<sup>st</sup> Annual Institute of Psychiatric Services Meeting of the American Psychiatric Association, New York, NY, U.S.A., October 9, 2015